Clinical trials: Single Dose
Biological Availability
Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions
An open label, single-center, balanced, randomized, two-treatment, two-sequence, four-period, full replicate, crossover, single dose, Phase I, oral comparative bioavailability study in healthy, adult participants (male subjects…
- Trial name
- NCT05439408
- Testing
- Dasatinib ASD 100 mg, Dasatinib 140 MG [Sprycel]
- Where
- India
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Xspray Pharma AB
Healthy Volunteers (HV)
A Study of IBI3042 in Healthy Adult Participants
This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042…
- Trial name
- NCT07842393
- Testing
- Investigational Drug: IBI3042
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fortvita Biologics (USA)Inc.
Healthy Volunteer
Mass Balance Study With MT-8554
This is a single-centre, open-label, mass balance study in healthy male subjects utilising a single oral dose of [14C] MT 8554.
- Trial name
- MT-8554 MB (NCT03381404)
- Testing
- [14C] MT-8554
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Adalimumab
A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants
To determine the pharmacokinetic (PK) comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) compared to ABP 501 40 mg/0.8 mL (ABP 501-LCF) following single-dose subcutaneous (SC) injection, as assessed principally by area under the…
- Trial name
- NCT05909852
- Testing
- ABP 501-HCF, ABP 501-LCF
- Where
- 3 sites in United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood
Single-rising dose (SRD) part: The main objectives of the SRD part of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 3009947 in healthy participants following oral administration of single…
- Trial name
- NCT07250048
- Testing
- BI 3009947 (Formulation A), BI 3009947 (Formulation B)
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus
The purposes of this study is to compare the test products Salmeterol/fluticasone Easyhaler with marketed product Seretide Diskus in terms of the drug absorbed into the blood stream
- Trial name
- NCT02162485
- Testing
- Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus
- Where
- Finland
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Healthy
Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects
A Phase 1, randomized, double-blind, placebo-controlled dose escalation trial of four dose cohorts of 10 subjects (1: 10mg, 2: 25mg, 3: 50mg, 4: 100mg).
- Trial name
- NCT04171115
- Testing
- G03-52-01
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults
The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, and a 6 month booster dose, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza…
- Trial name
- NCT00382187
- Testing
- MF59 adjuvanted H5N1 influenza vaccine
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Hepatic Insufficiency
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when…
- Trial name
- NCT02387814
- Testing
- Abemaciclib
- Where
- 5 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
The primary objective of this study is to determine the bioavailability of a FDC capsule formulation of dutasteride and tamsulosin hydrochloride (0.5 milligram [mg]/0.2 mg) relative to coadministration of one dutasteride 0.5 mg…
- Trial name
- NCT02509104
- Testing
- FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Study Investigating the Safety, Tolerability and Blood Concentration of the Substance SR-878
SR-878 is a newly developed medicine that aims to treat autoimmune disorders. It inhibits a protein (iRhom2), that regulates enzymes that are involved in the production of cytokines (small proteins that are crucial in controlling…
- Trial name
- NCT06607484
- Testing
- SR-878
- Where
- Austria
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- SciRhom GmbH
Healthy
Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers
To assess the safety and tolerability of single and multiple ascending intravenous doses of AAI101 (SAD \& MAD) in healthy male subjects.
- Trial name
- NCT03685084
- Testing
- AAI101 i.v., Saline 0.9% infusion, Piperacillin i.v.
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Allecra
Chronic Kidney Failure, Anaemia
Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects
A study to see how a single subcutaneous dose of Epoetin beta (NeoRecormon®) in healthy Japanese compares with a single subcutaneous dose of Epoetin beta (NeoRecormon®) in Caucasian Male subjects.
- Trial name
- NCT01085552
- Testing
- Epoetin Beta
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- InCROM Europe Clinical Research
Healthy
Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males
Study to determine the absorption of Nevirapine from different regions of the Gastro Intestinal tract.
- Trial name
- NCT02191189
- Testing
- Nevirapine suspension, into Enterion™ capsule, Nevirapine suspension
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Adolescent Asthma
Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study
Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy of subcutaneous injection of SHR-1905 in adolescent asthmatic subjects - an open-label, single-dose Phase II clinical study
- Trial name
- NCT06786455
- Testing
- SHR-1905 Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Indolent Systemic Mastocytosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).
- Trial name
- NCT02808793
- Testing
- AK002
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Allakos Inc.
Pulmonary Disease, Chronic Obstructive
HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the learning retention of the administration technique for the HandiHaler® vs. MDI and to compare the ease of use for HandiHaler® vs. MDI
- Trial name
- NCT02172404
- Testing
- Ipratropium metered dose inhaler (MDI)
- Volunteers
- 160 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase 1, single-center study to evaluate bioequivalence after co-administration of ALO and MET XR or administration of CT-L01 in healthy volunteers.
- Trial name
- NCT05363384
- Testing
- CT-L01, Alogliptin Benzoate 25 mg, Metformin HCl XR 1,000 mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Celltrion
Alpha Mannosidosis
Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
This is a single-center, open-label, dose escalation study of patients with alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous infusions of Lamazym.
- Trial name
- NCT01268358
- Testing
- Lamazym
- Volunteers
- 10 people
- Sponsor
- Zymenex A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.